Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis, a gene editing company listed on Nasdaq under the ticker CLLS, announced its share statistics as of July 31, 2021. The total number of shares in circulation is 45,465,310, while the total voting rights amount to 51,535,159. The company focuses on developing innovative CAR-T immunotherapies for oncology, utilizing their TALEN® gene editing technology and PulseAgile system. Cellectis aims to offer off-the-shelf gene-edited CAR T-cells and is dedicated to treating various cancers through its UCART product candidates.

Positive

• Developing innovative CAR-T immunotherapies targeting acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma.
• Utilizing advanced TALEN® gene editing technology and PulseAgile electroporation system.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
07/31/2021	45,465,310	51,535,159

About Cellectis
Cellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN^®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs.
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomial storage diseases.
Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com   
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com

IR contact:
Eric Dutang, Chief Financial Officer, +1 (646) 630 1748, investors@cellectis.com

 

Attachment

• Voting_Rights_PR_July_EN_docx

FAQ

What is the total number of shares for Cellectis as of July 31, 2021?

As of July 31, 2021, Cellectis has a total of 45,465,310 shares in circulation.

How many voting rights does Cellectis have as of July 31, 2021?

Cellectis has a total of 51,535,159 voting rights as of July 31, 2021.

What is Cellectis's focus in gene editing?

Cellectis focuses on developing CAR-T immunotherapies for cancer treatment using gene editing technology.

Which ticker symbol represents Cellectis on Nasdaq?

Cellectis is represented by the ticker symbol CLLS on Nasdaq.